Clinical Biochemistry, Drug Delivery & Therapy
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
Publications
Dose-response effect of pre-exercise carbohydrates under muscle glycogen unavailability: Insights from McArdle disease.
PMID: 38030066
Journal:
Year: 2023
Reference: J Sport Health Sci. 2023 Nov 27:S2095-2546(23)00115-1. doi: 10.1016/j.jshs.2023.11.006.
Impact factor:
Publication type: Paper in international publication
Authors: Alejo, Lidia B; Barranco-Gil, David; Bestard, Oriol; Bustos, Asuncion; Castellote-Belles, Laura; Couzi, Lionel; Fernandez-Ruiz, Mario; Ferrer-Costa, Roser; Kaminski, Hannah; Lucia, Alejandro et al.
DOI: 10.1016/j.jshs.2023.11.006
Postoperative complications after pancreatoduodenectomy for malignancy: results from the Recurrence After Whipple's (RAW) study.
PMID: 38036696
Journal: BJS Open
Year: 2023
Reference: BJS Open. 2023 Nov 1;7(6):zrad106. doi: 10.1093/bjsopen/zrad106.
Impact factor:
Publication type: Paper in international publication
Authors: Al-Sarrieh, Bilal A; Alejo, Lidia B; Alhaboob, Nassir; Aroori, Somaiah; Ausania, Fabio; Bari, Hassaan; Barranco-Gil, David; Bhogal, Ricky H; Bustos, Asuncion; Castellote-Belles, Laura et al.
DOI: 10.1093/bjsopen/zrad106
Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study.
PMID: 38068330
Journal: Journal of Clinical Medicine
Year: 2023
Reference: J Clin Med. 2023 Nov 24;12(23):7276. doi: 10.3390/jcm12237276.
Impact factor:
Publication type: Paper in international publication
Authors: Augustin, Salvador; Ferrer-Costa, Roser; Gabriel-Medina, Pablo; Guerrero, Rafael A; Jimenez-Masip, Alba; Marco, Andres; Munoz-Martinez, Sergio; On Behalf Of The Prisonafld Study Group Collaborators; Pericas, Juan M; Rivera-Esteban, Jesus et al.
DOI: 10.3390/jcm12237276
A new era for Advances in Laboratory Medicine.
PMID: 38075176
Journal: Advances in Laboratory Medicine
Year: 2023
Reference: Adv Lab Med. 2023 Sep 13;4(3):203-204. doi: 10.1515/almed-2023-0116. eCollection 2023 Sep.
Impact factor:
Publication type: Editorail in international publication
Authors: Arribas, Ignacio; Azpiroz, Fernando; Fernandez-Calle, Pilar; Ferrer-Costa, Roser; Gonzalez, Alvaro; Jimenez, Wladimiro; Livovsky, Dan M; Nieto, Adoracion et al.
DOI: 10.1515/almed-2023-0116
Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients.
PMID: 33603102
Journal: Scientific Reports
Year: 2021
Reference: Sci Rep. 2021 Feb 18;11(1):4215. doi: 10.1038/s41598-021-83762-4.
Impact factor:
Publication type: Paper in international publication
Authors: Buti, Maria; Carioti, Luca; Casillas, Rosario; Cortese, Maria Francesca; Esteban-Mur, Rafael; Garcia-Garcia, Selene; Godoy, Cristina; Gonzalez, Carolina; Gregori, Josep; Guerrero-Murillo, Mercedes et al.
DOI: 10.1038/s41598-021-83762-4
A multicenter blinded preclinical randomized controlled trial on Jak1/2 inhibition in MRL/MpJ-Fas(lpr) mice with proliferative lupus nephritis predicts low effect size.
PMID: 33607177
Journal: KIDNEY INTERNATIONAL
Year: 2021
Reference: Kidney Int. 2021 Jun;99(6):1331-1341. doi: 10.1016/j.kint.2021.01.024. Epub 2021 Feb 16.
Impact factor:
Publication type: Paper in international publication
Authors: Anders, Hans-Joachim; Boor, Peter; Bulow, Roman D; Jacobs-Cacha, Conxita; Lei, Yutian; Ortiz, Alberto; Sanchez-Nino, Maria D; Sehnert, Bettina; Soler, Maria Jose; Voll, Reinhard E et al.
DOI: 10.1016/j.kint.2021.01.024
Impact of Chemical Composition on the Nanostructure and Biological Activity of alpha-Galactosidase-Loaded Nanovesicles for Fabry Disease Treatment.
PMID: 33583172
Journal: ACS Applied Materials & Interfaces
Year: 2021
Reference: ACS Appl Mater Interfaces. 2021 Feb 24;13(7):7825-7838. doi: 10.1021/acsami.0c16871. Epub 2021 Feb 14.
Impact factor:
Publication type: Paper in international publication
Authors: Abasolo, Ibane; Camara-Sanchez, Patricia; Corchero, Jose Luis; Cordoba, Alba; Cristobal-Lecina, Edgar; Danino, Dganit; Diaz-Riascos, Zamira Vanessa; Garcia-Aranda, Natalia; Gonzalez-Mira, Elisabet; Gonzalez-Rioja, Ramon et al.
DOI: 10.1021/acsami.0c16871
Are Circulating FGF21 and NT-proBNP promising novel biomarkers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?
PMID: 33353469
Journal: ANTIOXIDANTS & REDOX SIGNALING
Year: 2021
Reference: Antioxid Redox Signal. 2021 Jun 20;34(18):1420-1427. doi: 10.1089/ars.2020.8230. Epub 2021 Feb 11.
Impact factor:
Publication type: Paper in international publication
Authors: Alegre-Martin, Jose; Castro-Marrero, Jesus; Cordobilla, Begona; Domingo, Joan Carles; Ferrer, Roser; Giralt, Marina et al.
DOI: 10.1089/ars.2020.8230
News
Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.
Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.
Researchers from all over Europe gathered to kick off the SPM4.0 project, an innovative Marie Curie Skłodowska (MSCA-DN) doctoral network that promotes the development of autonomous Scanning Probe Microscopy with AI.